The drug solidifies its place as a first-line treatment option in AML.
Gabriela Aponte-Melendez, PharmD
Advertisement
Articles by Gabriela Aponte-Melendez, PharmD
The program develops patient-centered oncology pharmacists through comprehensive training.
Advancements include novel combination therapies and improved diagnostic techniques.
Multiple P13K inhibitors have showed promise in treating genetically-mutated forms of breast cancer.
Advertisement
Latest Updated Articles
Shaping the Future of Oncology Pharmacy Through the NCODA Medically Integrated Oncology Pharmacy Residency ProgramPublished: December 27th 2024 | Updated:
Quizartinib in FLT3-ITD–Positive Acute Myeloid Leukemia: A New Era in Targeted TherapyPublished: February 25th 2025 | Updated:
The Evolution of PI3K Inhibitors in the Treatment of Breast CancerPublished: October 22nd 2024 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
COVID-19 mRNA Vaccines May Boost Immunotherapy Response in Cancer
2
Court Ruling Highlights Risks of Improper Dose Adjustments
3
States Push Forward on Insurance Mandates for GLP-1 and Obesity Treatments
4
Celebrating Pharmacists: Pharmacist Care Day in Pittsburgh
5
